Literature DB >> 24408788

Persistence with topical glaucoma therapy among newly diagnosed Japanese patients.

Kenji Kashiwagi1, Toshie Furuya.   

Abstract

PURPOSE: To investigate persistence with glaucoma medication use and factors associated with it among newly diagnosed Japanese patients. PATIENTS AND METHODS: The subjects of this study were Japanese patients entered in the Japan Health Insurance Society database who were newly diagnosed as having glaucoma and who had been prescribed antiglaucoma medication. Newly diagnosed was defined as having no history of glaucoma diagnosis, antiglaucoma medication use, or glaucoma surgery, including laser treatment, during at least 6 months prior to enrollment. Discontinuation of glaucoma medication was defined as no record of an antiglaucoma medication prescription or monthly claims for medical expenses for 6 months or longer. Patients who met the following criteria were eliminated from the analysis: those who changed insurance systems, those without records in the Japan Health Insurance Society database, or those whose glaucoma diagnosis was retracted.
RESULTS: A total of 2799 patients (age 47.3 ± 13.9 years) were defined as patients with newly diagnosed glaucoma. They comprised 1494 male (46.9 ± 13.6 years) and 1305 female (47.8 ± 14.1 years) patients. Soon after starting to take the antiglaucoma medication, many patients discontinued it. The persistence rates at 3 months, 6 months, 12 months, and 3 years after the initiation of medication were 73.2, 68.1, 60.9, and 52.5 %, respectively. Younger age, the number of medications, and the hospital size were significantly associated with the patients' persistence with medication use.
CONCLUSIONS: One-quarter of the newly diagnosed glaucoma patients discontinued glaucoma medication within the first 3 months of being prescribed it, and some factors were significantly associated with persistence with medication use.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24408788     DOI: 10.1007/s10384-013-0284-2

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  21 in total

1.  The influence of health literacy level on an educational intervention to improve glaucoma medication adherence.

Authors:  Kelly W Muir; Alice Ventura; Sandra S Stinnett; Abraham Enfiedjian; R Rand Allingham; Paul P Lee
Journal:  Patient Educ Couns       Date:  2011-10-13

2.  Efficiency of glaucoma drug regulation in 5 European countries: a 1995-2006 longitudinal prescription analysis.

Authors:  Renato De Natale; Claude Le Pen; Gilles Berdeaux
Journal:  J Glaucoma       Date:  2011 Apr-May       Impact factor: 2.503

3.  Effect of patient-centered communication training on discussion and detection of nonadherence in glaucoma.

Authors:  Steven R Hahn; David S Friedman; Harry A Quigley; Sameer Kotak; Elizabeth Kim; Meaghan Onofrey; Corey Eagan; Jack Mardekian
Journal:  Ophthalmology       Date:  2010-03-07       Impact factor: 12.079

4.  Patient-reported behavior and problems in using glaucoma medications.

Authors:  Betsy Sleath; Alan L Robin; David Covert; John E Byrd; Gail Tudor; Bonnie Svarstad
Journal:  Ophthalmology       Date:  2006-02-03       Impact factor: 12.079

5.  Persistence and adherence with topical glaucoma therapy.

Authors:  Beth L Nordstrom; David S Friedman; Essy Mozaffari; Harry A Quigley; Alexander M Walker
Journal:  Am J Ophthalmol       Date:  2005-10       Impact factor: 5.258

6.  Functional health literacy in patients with glaucoma in urban settings.

Authors:  Mark S Juzych; Sandeep Randhawa; Aman Shukairy; Padmini Kaushal; Anju Gupta; Nadia Shalauta
Journal:  Arch Ophthalmol       Date:  2008-05

7.  Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS).

Authors:  David S Friedman; Harry A Quigley; Laurie Gelb; Jason Tan; Jay Margolis; Sonali N Shah; Elizabeth E Kim; Thom Zimmerman; Steven R Hahn
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-11       Impact factor: 4.799

8.  Compliance in patients prescribed eyedrops for glaucoma.

Authors:  S C Patel; G L Spaeth
Journal:  Ophthalmic Surg       Date:  1995 May-Jun

9.  Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic.

Authors:  O Kosoko; H A Quigley; S Vitale; C Enger; L Kerrigan; J M Tielsch
Journal:  Ophthalmology       Date:  1998-11       Impact factor: 12.079

10.  Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage.

Authors:  Shinya Kimura; Toshihiko Sato; Shunya Ikeda; Mitsuhiko Noda; Takeo Nakayama
Journal:  J Epidemiol       Date:  2010-08-07       Impact factor: 3.211

View more
  15 in total

1.  One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.

Authors:  Hiroshi Inazaki; Satoshi Kobayashi; Yoko Anzai; Hisayoshi Satoh; Shimpei Sato; Maiko Inoue; Shin Yamane; Kazuaki Kadonosono
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-15       Impact factor: 3.117

2.  iStent inject® and cataract surgery for mild-to-moderate primary open angle glaucoma in Japan: a cost-utility analysis.

Authors:  Ataru Igarashi; Kyoko Ishida; Nobuyuki Shoji; Alice Chu; Heather Falvey; Ru Han; Maki Ueyama; Yoshie Onishi
Journal:  Int J Ophthalmol       Date:  2022-06-18       Impact factor: 1.645

3.  Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan.

Authors:  Masaki Tanito
Journal:  J Pers Med       Date:  2022-06-11

4.  Prostaglandin-associated periorbitopathy in latanoprost users.

Authors:  Shunsuke Nakakura; Minamai Yamamoto; Etsuko Terao; Nozomi Nagatomi; Naoko Matsuo; Yausko Fujisawa; Yuki Fujio; Hitoshi Tabuchi; Yoshiaki Kiuchi
Journal:  Clin Ophthalmol       Date:  2014-12-30

5.  Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients.

Authors:  Makoto Aihara; Misato Adachi; Hiroshi Matsuo; Tetsuya Togano; Takeo Fukuchi; Noriyuki Sasaki
Journal:  Acta Ophthalmol       Date:  2017-04-03       Impact factor: 3.761

6.  Changes in Glaucoma Medication during the Past Eight Years and Future Directions in Japan Based on an Insurance Medical Claim Database.

Authors:  Masako Sakamoto; Kazuyoshi Kitamura; Kenji Kashiwagi
Journal:  J Ophthalmol       Date:  2017-10-31       Impact factor: 1.909

7.  Long Term Glaucoma Drug Delivery Using a Topically Retained Gel/Microsphere Eye Drop.

Authors:  Morgan V Fedorchak; Ian P Conner; Joel S Schuman; Anthony Cugini; Steven R Little
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

8.  The clinical effectiveness of tafluprost on Japanese normal-tension glaucoma patients.

Authors:  Akio Nomura; Hirotaka Osaki; Fumiki Shimada; Yasuaki Kuwayama
Journal:  Clin Ophthalmol       Date:  2018-03-20

9.  Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study.

Authors:  Hidenobu Tanihara; Takahiko Kakuda; Tetsuro Sano; Takashi Kanno; Ryoji Gunji
Journal:  BMC Ophthalmol       Date:  2020-07-09       Impact factor: 2.209

10.  Association between topical β-blocker use and asthma attacks in glaucoma patients with asthma: a cohort study using a claims database.

Authors:  Ai Kido; Masahiro Miyake; Tadamichi Akagi; Hanako Ohashi Ikeda; Takanori Kameda; Kenji Suda; Tomoko Hasegawa; Shusuke Hiragi; Satomi Yoshida; Akitaka Tsujikawa; Hiroshi Tamura; Koji Kawakami
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-09       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.